View Item 

Show simple item record

The protease‐activated receptor 4 Ala120Thr variant alters platelet responsiveness to low‐dose thrombin and protease‐activated receptor 4 desensitization, and is blocked by non‐competitive P2Y12 inhibition
dc.contributor.authorWhitley, M. J.
dc.contributor.authorHenke, D. M.
dc.contributor.authorGhazi, A.
dc.contributor.authorNieman, M.
dc.contributor.authorStoller, M.
dc.contributor.authorSimon, L. M.
dc.contributor.authorChen, E.
dc.contributor.authorVesci, J.
dc.contributor.authorHolinstat, M.
dc.contributor.authorMcKenzie, S. E.
dc.contributor.authorShaw, C. A.
dc.contributor.authorEdelstein, L. C.
dc.contributor.authorBray, P. F.
dc.date.accessioned2018-12-06T17:37:13Z
dc.date.available2020-01-09T19:40:13Zen
dc.date.issued2018-12
dc.identifier.citationWhitley, M. J.; Henke, D. M.; Ghazi, A.; Nieman, M.; Stoller, M.; Simon, L. M.; Chen, E.; Vesci, J.; Holinstat, M.; McKenzie, S. E.; Shaw, C. A.; Edelstein, L. C.; Bray, P. F. (2018). "The protease‐activated receptor 4 Ala120Thr variant alters platelet responsiveness to low‐dose thrombin and protease‐activated receptor 4 desensitization, and is blocked by non‐competitive P2Y12 inhibition." Journal of Thrombosis and Haemostasis (12): 2501-2514.
dc.identifier.issn1538-7933
dc.identifier.issn1538-7836
dc.identifier.urihttps://hdl.handle.net/2027.42/146616
dc.publisherWiley Periodicals, Inc.
dc.subject.otherstroke
dc.subject.otherblood platelets
dc.subject.otherreceptors
dc.subject.othergenetic variation
dc.subject.otherthrombin
dc.titleThe protease‐activated receptor 4 Ala120Thr variant alters platelet responsiveness to low‐dose thrombin and protease‐activated receptor 4 desensitization, and is blocked by non‐competitive P2Y12 inhibition
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146616/1/jth14318_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146616/2/jth14318.pdf
dc.identifier.doi10.1111/jth.14318
dc.identifier.sourceJournal of Thrombosis and Haemostasis
dc.identifier.citedreferenceFumagalli M, Moltke I, Grarup N, Racimo F, Bjerregaard P, Jorgensen ME, Korneliussen TS, Gerbault P, Skotte L, Linneberg A, Christensen C, Brandslund I, Jorgensen T, Huerta‐Sanchez E, Schmidt EB, Pedersen O, Hansen T, Albrechtsen A, Nielsen R. Greenlandic Inuit show genetic signatures of diet and climate adaptation. Science 2015; 349: 1343 – 7.
dc.identifier.citedreferenceArachiche A, de la Fuente M, Nieman MT. Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets. PLoS ONE 2013; 8: e55740.
dc.identifier.citedreferenceShrimpton CN, Borthakur G, Larrucea S, Cruz MA, Dong JF, Lopez JA. Localization of the adhesion receptor glycoprotein Ib‐IX‐V complex to lipid rafts is required for platelet adhesion and activation. J Exp Med 2002; 196: 1057 – 66.
dc.identifier.citedreferenceMumaw MM, de la Fuente M, Arachiche A, Wahl JK, Nieman MT. Development and characterization of monoclonal antibodies against protease activated receptor 4 (PAR4). Thromb Res 2015; 135: 1165 – 71.
dc.identifier.citedreferenceMeschia JF, Arnett DK, Ay H, Brown RD Jr, Benavente OR, Cole JW, de Bakker PI, Dichgans M, Doheny KF, Fornage M, Grewal RP, Gwinn K, Jern C, Conde JJ, Johnson JA, Jood K, Laurie CC, Lee JM, Lindgren A, Markus HS, et al. Stroke Genetics Network (SiGN) study: design and rationale for a genome‐wide association study of ischemic stroke subtypes. Stroke 2013; 44: 2694 – 702.
dc.identifier.citedreferenceAdams HP Jr, Biller J. Classification of subtypes of ischemic stroke: history of the trial of org 10172 in acute stroke treatment classification. Stroke 2015; 46: e114 – 17.
dc.identifier.citedreferencePurcell S, Neale B, Todd‐Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole‐genome association and population‐based linkage analyses. Am J Hum Genet 2007; 81: 559 – 75.
dc.identifier.citedreferencePavic G, Grandoch M, Dangwal S, Jobi K, Rauch BH, Doller A, Oberhuber A, Akhyari P, Schror K, Fischer JW, Fender AC. Thrombin receptor protease‐activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus. Circulation 2014; 130: 1700 – 11.
dc.identifier.citedreferenceVu TKH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057 – 68.
dc.identifier.citedreferenceDe Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par‐1 on intact platelets. J Biol Chem 2001; 276: 4692 – 8.
dc.identifier.citedreferenceWard CM, Andrews RK, Smith AI, Berndt MC. Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Ibalpha. Identification of the sulfated tyrosine/anionic sequence Tyr‐276‐Glu‐282 of glycoprotein Ibalpha as a binding site for von Willebrand factor and alpha‐thrombin. Biochemistry 1996; 35: 4929 – 38.
dc.identifier.citedreferenceTourdot BE, Stoveken H, Trumbo D, Yeung J, Kanthi Y, Edelstein LC, Bray PF, Tall GG, Holinstat M. Genetic variant in human PAR (protease‐activated receptor) 4 enhances thrombus formation resulting in resistance to antiplatelet therapeutics. Arterioscler Thromb Vasc Biol 2018; 38: 1632 – 43.
dc.identifier.citedreferenceCovic L, Singh C, Smith H, Kuliopulos A. Role of the PAR4 thrombin receptor in stabilizing platelet–platelet aggregates as revealed by a patient with Hermansky–Pudlak syndrome. Thromb Haemost 2002; 87: 722 – 7.
dc.identifier.citedreferenceFalker K, Haglund L, Gunnarsson P, Nylander M, Lindahl TL, Grenegard M. Protease‐activated receptor 1 (PAR1) signalling desensitization is counteracted via PAR4 signalling in human platelets. Biochem J 2011; 436: 469 – 80.
dc.identifier.citedreferenceAdam F, Guillin MC, Jandrot‐Perrus M. Glycoprotein Ib‐mediated platelet activation. A signalling pathway triggered by thrombin. Eur J Biochem 2003; 270: 2959 – 70.
dc.identifier.citedreferenceCarlson CS, Matise TC, North KE, Haiman CA, Fesinmeyer MD, Buyske S, Schumacher FR, Peters U, Franceschini N, Ritchie MD, Duggan DJ, Spencer KL, Dumitrescu L, Eaton CB, Thomas F, Young A, Carty C, Heiss G, Le Marchand L, Crawford DC, et al. Generalization and dilution of association results from European GWAS in populations of non‐European ancestry: the PAGE study. PLoS Biol 2013; 11: e1001661.
dc.identifier.citedreferenceIvanciu L, Krishnaswamy S, Camire RM. New insights into the spatiotemporal localization of prothrombinase in vivo. Blood 2014; 124: 1705 – 14.
dc.identifier.citedreferenceWelsh JD, Stalker TJ, Voronov R, Muthard RW, Tomaiuolo M, Diamond SL, Brass LF. A systems approach to hemostasis: 1. The interdependence of thrombus architecture and agonist movements in the gaps between platelet. Blood 2014; 124: 1808 – 15.
dc.identifier.citedreferenceTomaiuolo M, Stalker TJ, Welsh JD, Diamond SL, Sinno T, Brass LF. A systems approach to hemostasis: 2. Computational analysis of molecular transport in the thrombus microenvironment. Blood 2014; 124: 1816 – 23.
dc.identifier.citedreferenceStalker TJ, Welsh JD, Tomaiuolo M, Wu J, Colace TV, Diamond SL, Brass LF. A systems approach to hemostasis: 3. Thrombus consolidation regulates intrathrombus solute transport and local thrombin activity. Blood 2014; 124: 1824 – 31.
dc.identifier.citedreferenceWelsh JD, Colace TV, Muthard RW, Stalker TJ, Brass LF, Diamond SL. Platelet‐targeting sensor reveals thrombin gradients within blood clots forming in microfluidic assays and in mouse. J Thromb Haemost 2012; 10: 2344 – 53.
dc.identifier.citedreferenceBrass LF, Manning DR, Williams AG, Woolkalis MJ, Poncz M. Receptor and G protein‐mediated responses to thrombin in HEL cells. J Biol Chem 1991; 266: 958 – 65.
dc.identifier.citedreferenceHoxie JA, Ahuja M, Belmonte E, Pizarro S, Parton R, Brass LF. Internalization and recycling of activated thrombin receptors. J Biol Chem 1993; 268: 13756 – 63.
dc.identifier.citedreferenceShapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease‐activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem 2000; 275: 25216 – 21.
dc.identifier.citedreferenceKahn ML, Nakanishi‐Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease‐activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879 – 87.
dc.identifier.citedreferenceKhan A, Li D, Ibrahim S, Smyth E, Woulfe DS. The physical association of the P2Y12 receptor with PAR4 regulates arrestin‐mediated Akt activation. Mol Pharmacol 2014; 86: 1 – 11.
dc.identifier.citedreferenceSmith TH, Li JG, Dores MR, Trejo J. Protease‐activated receptor‐4 and P2Y12 dimerize, co‐internalize and activate Akt signaling via endosomal recruitment of beta‐arrestin. J Biol Chem 2017; 292: 13867 – 78.
dc.identifier.citedreferenceKim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP. Protease‐activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002; 99: 3629 – 36.
dc.identifier.citedreferenceLam JY, Latour JG, Lesperance J, Waters D. Platelet aggregation, coronary artery disease progression and future coronary events. Am J Cardiol 1994; 73: 333 – 8.
dc.identifier.citedreferenceWong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, Allegretto N, Hua J, Harden D, Guay J, Callejo M, Miller MM, Lawrence RM, Banville J, Guy J, Maxwell BD, Priestley ES, Marinier A, Wexler RR, Bouvier M, et al. Blockade of protease‐activated receptor‐4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med 2017; 9: eaaf5294.
dc.identifier.citedreferenceHolinstat M, Bray PF. Protease receptor antagonism to target blood platelet therapies. Clin Pharmacol Ther 2016; 99: 72 – 81.
dc.identifier.citedreferenceCoughlin SR. Thrombin signalling and protease‐activated receptors. Nature 2000; 407: 258 – 64.
dc.identifier.citedreferenceJamieson GA. Pathophysiology of platelet thrombin receptors. Thromb Haemost 1997; 78: 242 – 6.
dc.identifier.citedreferenceKahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690 – 4.
dc.identifier.citedreferenceJacques SL, Kuliopulos A. Protease‐activated receptor‐4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. Biochem J 2003; 376: 733 – 40.
dc.identifier.citedreferenceMathews II, Padmanabhan KP, Ganesh V, Tulinsky A, Ishii M, Chen J, Turck CW, Coughlin SR, Fenton JW 2nd. Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes. Biochemistry 1994; 33: 3266 – 79.
dc.identifier.citedreferenceCovic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000; 39: 5458 – 67.
dc.identifier.citedreferenceFrench SL, Arthur JF, Lee H, Nesbitt WS, Andrews RK, Gardiner EE, Hamilton JR. Inhibition of protease‐activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood. J Thromb Haemost 2016; 14: 1642 – 54.
dc.identifier.citedreferenceEdelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, Kong X, Nagalla S, Mohandas N, Cohen DE, Dong JF, Shaw C, Bray PF. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR‐376c. Nat Med 2013; 19: 1609 – 16.
dc.identifier.citedreferenceEdelstein LC, Simon LM, Lindsay CR, Kong X, Teruel‐Montoya R, Tourdot BE, Chen ES, Ma L, Coughlin S, Nieman M, Holinstat M, Shaw CA, Bray PF. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 2014; 124: 3450 – 8.
dc.identifier.citedreferenceTourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M. Mechanism of race‐dependent platelet activation through the protease‐activated receptor‐4 and Gq signaling axis. Arterioscler Thromb Vasc Biol 2014; 34: 2644 – 50.
dc.identifier.citedreferenceFaruqi TR, Weiss EJ, Shapiro MJ, Huang W, Coughlin SR. Structure‐function analysis of protease‐activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem 2000; 275: 19728 – 34.
dc.identifier.citedreferenceMcLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, Hamm HE. Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease‐activated receptor‐1. J Biol Chem 2005; 280: 25048 – 59.
dc.identifier.citedreferenceLeger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade‐Gordon P, Covic L, Kuliopulos A. Blocking the protease‐activated receptor 1‐4 heterodimer in platelet‐mediated thrombosis. Circulation 2006; 113: 1244 – 54.
dc.identifier.citedreferenceTricoci P, Neely M, Whitley MJ, Edelstein LC, Simon LM, Shaw C, Fortina P, Moliterno DJ, Armstrong PW, Aylward P, White H, Van de Werf F, Jennings LK, Wallentin L, Held C, Harrington RA, Mahaffey KW, Bray PF. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: analysis from the TRACER trial. Blood Cells Mol Dis 2018; 72: 37 – 43.
dc.identifier.citedreferenceMustard JF, Kinlough‐Rathbone RL, Packham MA. Isolation of human platelets from plasma by centrifugation and washing. Methods Enzymol 1989; 169: 3 – 11.
dc.identifier.citedreferenceYee DL, Bergeron AL, Sun CW, Dong JF, Bray PF. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 2006; 4: 2043 – 50.
dc.identifier.citedreferenceWu CC, Wu SY, Liao CY, Teng CM, Wu YC, Kuo SC. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3‐kinase pathway in maintaining thrombin‐induced platelet aggregation. Br J Pharmacol 2010; 161: 643 – 58.
dc.identifier.citedreferenceDubois C, Steiner B, Kieffer N, Reigner SC. Thrombin binding to GPIbalpha induces platelet aggregation and fibrin clot retraction supported by resting alphaIIbbeta3 interaction with polymerized fibrin. Thromb Haemost 2003; 89: 853 – 65.
dc.identifier.citedreferenceQuinton TM, Kim S, Derian CK, Jin J, Kunapuli SP. Plasmin‐mediated activation of platelets occurs by cleavage of protease‐activated receptor 4. J Biol Chem 2004; 279: 18434 – 9.
dc.identifier.citedreferenceArachiche A, Mumaw MM, de la Fuente M, Nieman MT. Protease‐activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1‐enhanced cleavage of PAR4 by alpha‐thrombin. J Biol Chem 2013; 288: 32553 – 62.
dc.identifier.citedreferencede la Fuente M, Noble DN, Verma S, Nieman MT. Mapping human protease‐activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4. J Biol Chem 2012; 287: 10414 – 23.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jth14318_am.pdf
Size:
911.7KB
Format:
PDF
View/Open
Name:
jth14318.pdf
Size:
1.007MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.